Dr. Jörg Neermann
Jörg Neermann, PhD, joined LSP in 2007 as Partner. Jörg’s prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Jörg was the Managing Director of Deutsche Bank’s DVC, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector.
Jörg brings a strong scientific background and hands-on finance and investment expertise to the LSP team. He has been appointed a Director at a large number of companies, all of which he has helped with his scientific expertise, biotechnology experience and global networks. Among others, Jörg is currently a Director at Probiodrug, a German biotech company that went public on Euronext Amsterdam in 2014 and is active in the development of novel, disease modifying therapeutics against Alzheimer’s disease.
Jörg holds a Master’s degree and a PhD in Biotechnology from the Technical University in Braunschweig and MIT in Cambridge, US. He also studied economics at Harvard Business School, US. Jörg lives in Munich with his wife and two children.
Dr. Gerhard Ries
Dr. Gerhard Ries is Managing Partner of LifeCare Partners, a dedicated VC/PE firm in the European healthcare sector. Mr. Ries has more than 20 years of global pharma industry and VC experience as both entrepreneur and investor. He has a strong scientific and operational background and held various corporate positions at McKinsey, Novartis, and Roche (Boehringer Mannheim).
Mr. Ries was Founder and Managing Partner of BioMedPartners where he supervised more than 50 investments and served on the board of more than 20 companies, including 4-Antibody, Activaero, Affimed, Curetis, Delenex, Develco Pharma, Esbatech, Eyesense, Glycart, Lipomed, Vaximm, etc. Mr. Ries holds a M.S. and Ph.D. degree in Molecular Biology from the University of Basel and a M.S. degree in Biotechnology from the Fachhochschule Weihenstephan (Munich).
Dr. Thomas Taapken
Dr. Taapken spent more than five years at Epigenomics AG, initially as CFO and subsequently, from October 2012, as its CEO/CFO. He led the company’s efforts in gaining regulatory approval for the first blood-based molecular diagnostic cancer screening test by the FDA and oversaw its subsequent introduction into the US market. Before his time at Epigenomics, Dr. Taapken served as CFO at Biotie Therapies Corp. (now Acorda Therapeutics) and its predecessor companies for six years.
His extensive international experience in the life sciences industry also includes over seven years as a venture capital investor at DVC Deutsche Venture Capital and San Francisco-based US venture capital firm Burrill & Company. Prior to that, he worked several years at Sanofi (originally Hoechst AG) in the United States and Germany, managing corporate venture capital activities, as well as in the areas of corporate & business development and research.
Throughout his career, Dr. Taapken has been involved in numerous transactions spanning acquisitions, mergers and divestitures and helped to raise over EUR 100m through private and public offerings for those companies where he served in executive positions
Jan Van den Bossche
Jan Van den Bossche holds a Master Degree in Applied Economic Sciences at the KULeuven. He worked for more than 12 years as a biotech analyst at Petercam.
He was involved in numerous public and private transactions of Belgian and Dutch Biotech companies, such as ThromoboGenics, Tigenix, UCB, AMT (Uniqure), IBA, MDxHealth.
Before he joined Fund+, he was for more than 2 years part of the investor relations team at the Dutch life sciences and materials sciences company DSM (Geleen, NL).
Vincent Ossipow, Ph.D., CFA joined Omega Funds as a Partner in 2014 and brings 19 years of healthcare investment experience in public and private companies. He is the Board of Directors of several private and listed life science companies.
Previously, Vincent worked with Sectoral Asset Management, one of the largest North American healthcare institutional investor, as a Partner for Private Equity. From 2000 to 2006 he worked as a research fellow at the University of Geneva on the molecular basis of brain function. He also acted as Sectoral Asset Management’s Chief Scientific Officer during these years. Previously, he worked at Pictet Bank as a research analyst for biotechnology equities and as a co-manager of the Pictet Biotech Fund, an over 1bn USD listed investment vehicle.
Vincent trained as a postdoctoral fellow (Hoffman-La-Roche and Human Frontier Science Program fellow) in Geneva and at the National Cancer Institute NCI in Bethesda, Maryland, and completed a Certificate in International Finance and Global Markets at the Georgetown University School of Business in Washington, D.C. He trained with a Master’s Degree in computational sciences in 1991, a Master’s Degree in molecular biology in 1992, and a Ph.D. in molecular biology in 1996, all from the University of Geneva.
His work has been published in major journals (sample): PNAS, Cell, Molecular and Cell Biology and in 2014 he co-authored a book for Springer/Humana Press on monoclonal antibodies (“Monoclonal Antibodies”, Methods in Molecular Biology).